JP2008513354A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513354A5
JP2008513354A5 JP2007522632A JP2007522632A JP2008513354A5 JP 2008513354 A5 JP2008513354 A5 JP 2008513354A5 JP 2007522632 A JP2007522632 A JP 2007522632A JP 2007522632 A JP2007522632 A JP 2007522632A JP 2008513354 A5 JP2008513354 A5 JP 2008513354A5
Authority
JP
Japan
Prior art keywords
composition
antibody
cancer cells
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007522632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513354A (ja
Filing date
Publication date
Priority claimed from US10/894,672 external-priority patent/US9249229B2/en
Priority claimed from US10/996,316 external-priority patent/US7408041B2/en
Priority claimed from US11/171,567 external-priority patent/US20060057651A1/en
Application filed filed Critical
Publication of JP2008513354A publication Critical patent/JP2008513354A/ja
Publication of JP2008513354A5 publication Critical patent/JP2008513354A5/ja
Withdrawn legal-status Critical Current

Links

JP2007522632A 2004-07-20 2005-07-19 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用 Withdrawn JP2008513354A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/894,672 US9249229B2 (en) 2000-12-08 2004-07-20 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US10/996,316 US7408041B2 (en) 2000-12-08 2004-11-23 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US11/171,567 US20060057651A1 (en) 2000-12-08 2005-06-30 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
PCT/US2005/025488 WO2006020266A2 (en) 2004-07-20 2005-07-19 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012053212A Division JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Publications (2)

Publication Number Publication Date
JP2008513354A JP2008513354A (ja) 2008-05-01
JP2008513354A5 true JP2008513354A5 (https=) 2008-08-14

Family

ID=35907987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007522632A Withdrawn JP2008513354A (ja) 2004-07-20 2005-07-19 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用
JP2012053212A Expired - Fee Related JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012053212A Expired - Fee Related JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Country Status (8)

Country Link
US (4) US20060057651A1 (https=)
EP (2) EP2441777B1 (https=)
JP (2) JP2008513354A (https=)
AU (1) AU2005274785B2 (https=)
CA (1) CA2574488C (https=)
DK (1) DK2441777T3 (https=)
ES (1) ES2569240T3 (https=)
WO (1) WO2006020266A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
HUE032563T2 (en) * 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
AU2016228280B2 (en) * 2007-07-12 2019-02-21 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8252285B2 (en) * 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
JP2011516840A (ja) * 2008-04-04 2011-05-26 トリリウム セラピューティクス インコーポレーティッド 可溶性ｃｄ２００に関するアッセイ法
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9382534B2 (en) 2011-10-05 2016-07-05 Ge Healthcare Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
ES2952064T3 (es) * 2015-12-16 2023-10-26 Walter & Eliza Hall Inst Medical Res Inhibición de la proteína SH2 inducida por citocinas en células NK
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20190048055A1 (en) * 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
CN109239334A (zh) * 2018-09-10 2019-01-18 吉林大学 建立时间分辨荧光免疫层析法检测MxA试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109633142B (zh) * 2018-12-22 2021-08-27 中国人民解放军第四军医大学 一种急性髓细胞性白血病诊断模型的建立方法及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
JPH0246297A (ja) * 1988-08-08 1990-02-15 Takeda Chem Ind Ltd モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5728815A (en) 1992-03-30 1998-03-17 Board Of Regents, The University Of Texas System Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
EP0858506A4 (en) * 1995-10-31 2004-12-08 Uab Research Foundation GENETIC INDUCTION OF RECEPTORS TO TARGETED RADIOTHERAPY
AU1144097A (en) 1995-12-08 1997-07-03 Brigham And Women's Hospital Ox-2 costimulatory molecule
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US7291330B2 (en) * 2000-03-17 2007-11-06 Trillium Therapeutics Inc. MD-1 inhibitors as immune suppressants
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
CA2429579A1 (en) * 2000-11-22 2002-05-30 Trillium Therapeutics Inc. Truncated cd200
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7427665B2 (en) * 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
US7306906B2 (en) 2001-09-19 2007-12-11 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
MXPA05006978A (es) 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
EP1606387A4 (en) 2003-03-04 2008-04-23 Alexion Pharma Inc VECTORS USED TO PRODUCE CONSTANT HYBRID AREAS
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
US8815235B2 (en) * 2004-06-02 2014-08-26 Jan E. Schnitzer Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE028179T2 (en) 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Similar Documents

Publication Publication Date Title
JP2008513354A5 (https=)
CN111630070B (zh) 三特异性蛋白质及使用方法
CN104379602B (zh) 具有条件活性的抗表皮生长因子受体抗体及其使用方法
KR101017732B1 (ko) 내재화 항-ｃｄ74 항체 및 그 이용방법
US9758589B2 (en) Methods for enhancing anti-tumor antibody therapy
JP5214252B2 (ja) ヒト化ｌ２４３抗体
JP6248024B2 (ja) ヒトｏｘ４０受容体に対する結合分子
CN114007699A (zh) 拮抗剂抗cd7抗体
CN109843325A (zh) Cd3结合抗体
CN111886015B (zh) 用于同种异体嵌合抗原受体t细胞的给药的方法和组合物
KR20160097336A (ko) 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
RU2016107096A (ru) Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
JP2018529635A5 (https=)
JP2021167324A (ja) がん治療のための集中インターフェロン免疫療法
US20130315820A1 (en) Use of an antibody directed against a membrane protein
US12098201B2 (en) Anti-TIM3 monoclonal antibodies and chimeric antigen receptors
CN106243225A (zh) 新型抗-pd-l1抗体
Gorovits et al. Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics: B. Gorovits et al.
JP2019511199A (ja) 新規の抗ｕｐｋ１ｂ抗体及び使用方法
JP2023516195A (ja) Ｃ１９ ｃ３８二特異性抗体
US20240374644A1 (en) Herv-k antibody therapeutics
Daniels et al. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies
WO2020018580A1 (en) Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell
Zhang et al. A humanized anti-MSLN× 4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
CN119053340A (zh) 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症